peter attia tirzepatide 246 - AMA #45: Pros and cons of GLP-1 weight loss drugs and metformin as a geroprotective agent Dr. Peter Attia reminds us:

Functional architecture of the retromer cargo-recognition complex

approved for the treatment of persons living with obesity with anything beyond a claim of cardiovascular safety." The decision, McGuire said, reinforces what most medical experts have known for decades "that reducing body weight for persons living with obesity would reduce risk for a broad spectrum of obesity-related complications, cardiovascular and otherwise." McGuire, who is an expert in heart disease and prevention, especially among people with diabetes , predicts that approximately one in five U.S

What are the most common side effects of GLP-1 medication

In 2023, a secondary analysis of the trial data was conducted to retrospectively evaluate the risk of atrial fibrillation among the participants (Virtanen 2023)